Christine Ryan, MD

@ChristineRyanMD

Hematologist/Oncologist in #lymphoma @DanaFarber @harvardmed | Alum @BrighamWomens Internal Medicine Residency | MD @StanfordMed | SF Giants Fan | Tweets my own

Boston, MA Joined December 2021

133 Following 239 Followers 49 Posts

Latest posts 5

Christine Ryan, MD @ChristineRyanMD Jan 30, 2023

Thrilled to have had the opportunity to help write up the results of this multi-center IST of ibrutinib + obin in R/R CLL led by @DrMDavids and to share our publication here! rdcu.be/c4sbD Grateful as always for Matt's incredible mentorship. @DanaFarberNews @DanaFarber

Matthew Davids, MD, MMSc @DrMDavids Jan 30, 2023

Happy to share our new pub on our ph1b IST of ibrut + obin for R/R CLL rdcu.be/c4sbD @leukemiajnl @DanaFarber

View quoted post on X

Christine Ryan, MD @ChristineRyanMD Dec 11, 2022

Huge congratulations to my amazing co-fellow and friend @beckyzon on her #ASH22 presentation on a highly effective implementation of EMR alerts to improve management of HIT! @BrighamHeme @DanaFarber

Christine Ryan, MD @ChristineRyanMD Dec 11, 2022

Key results from our presentation yesterday summarized nicely here - thanks @Eddie_Cliff! AVO is a highly-active and well-tolerated triplet in a 1L CLL population enriched for high-risk disease. @DrMDavids @DanaFarber @DanaFarberNews #ASH22

Eddie Cliff @Eddie_Cliff Dec 10, 2022

Impressive and so far durable responses to AVO in newly-diagnosed CLL: at median followup of 35 months, 92.6% of patients are progression-free and alive @ChristineRyanMD @DrMDavids #ASH22 #lymsm

View quoted post on X

Christine Ryan, MD @ChristineRyanMD Dec 11, 2022

This was all only possible because of the study’s lead investigator and my incredible mentor @DrMDavids. Many, many thanks to him for the generous opportunity to present these results yesterday! #ASH22 @DanaFarber @DanaFarberNews

Dana-Farber News Verified account @DanaFarberNews Dec 10, 2022

Presenting her findings to a packed auditorium, @DanaFarber Christine Ryan, M.D. explains how a triple regimen of AVO was shown highly effective in patients with high-risk forms of Chronic Lymphocytic Leukemia. #ASH22

View quoted post on X

Christine Ryan, MD @ChristineRyanMD Aug 24, 2022

Very honored to receive the 2022 Young Investigator Award from @CllSociety! Grateful for their generous support for our research as we strive to make advances in the treatment of #RichtersSyndrome, a significant unmet need in #CLL. @DrMDavids @DanaFarber

CLL Society Inc. Verified account @CllSociety Aug 23, 2022

Announcing @ChristineRyanMD as the winner of our first-ever Young Investigator Award! Her #research under the mentorship of @DrMDavids from @DanaFarber will help to further understand #RichtersSyndrome in #CLL and #SLL. bit.ly/3QYOCCp #MedTwitter #hemonc #fellow

View quoted post on X